BYSI

Plinabulin

All Cancer

Stage (next event)

Expected Date

Phase 3 (NDA Submission)

Q1 2021

Catalyst Info & Data Links

TITLE: Plinabulin for All Cancer (CIN)  - Phase 3 

  • ClinicalTrial.gov (NCT03102606): Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

  • ClinicalTrial.gov (NCT03294577): Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia


WHAT IS THE NEXT CATALYST EVENT?

  • NDA Submission For Plinabulin For CIN In The U.S.


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Early 2021


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • Plinabulin binds to and affects the function of the protein tubulin within cells of the body, in a manner recently demonstrated to differ significantly from all other approved or advanced tubulin targeting agents. Tubulin aggregates or polymerizes inside cells to form strands called microtubules that have different functions indifferent cells. Therefore disrupting microtubules with Plinabulin has different effects in different cell types in the body.

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon